Arcutis Biotherapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Heron Patrick J, was filed 17 Jun 2025.
Who traded when
BuySale+8 other insiders
Since the insiders bought
- +91.7%Entry US$13.67 · Close at T+365 US$26.21
- +147.1%Entry US$12.61 · Close at T+365 US$31.16
- +147.1%Entry US$12.61 · Close at T+365 US$31.16
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Arcutis Biotherapeutics, Inc. Strong Buy (bullish), based on 8 analysts. Average price target: US$39.13.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 40,000 shares@ US$34.3168CommonSEC144:0001628280-26-070283
- 1,219 shares@ US$31.86340.0010% mcap0.8% of flowCommon StockSEC:0001628280-26-070385:0
- 40,000 shares@ US$3.640.0036% mcap3.0% of flowCommon StockSEC:0001628280-26-070385:1
- 40,000 shares@ US$34.31680.034% mcap27.8% of flowCommon StockSEC:0001628280-26-070385:2
- 943 shares@ US$31.86340.0008% mcap0.5% of flowCommon StockSEC:0001628280-26-070383:0
- 4,377 shares@ US$31.86340.0035% mcap2.5% of flowCommon StockSEC:0001628280-26-070381:0
- 943 shares@ US$31.86340.0007% mcap6.2% of flowCommonSEC144:0001628280-26-068984
- 1,219 shares@ US$31.86340.0010% mcap10.6% of flowCommonSEC144:0001628280-26-068986
- 4,377 shares@ US$31.86340.0035% mcap100.0% of flowCommonSEC144:0001628280-26-068988
- 2,819 shares0Common StockSEC:0001628280-26-067898:0
- 60,376 shares@ US$33.000.050% mcap19.3% of flowCommonSEC144:0001628280-26-066520
- 1,018 shares@ US$7.510.0002% mcap0.2% of flowCommon StockSEC:0001628280-26-066331:1
- 2,254 shares@ US$8.630.0005% mcap0.4% of flowCommon StockSEC:0001628280-26-066331:2
- 4,728 shares@ US$26.930.0035% mcap2.7% of flowCommon StockSEC:0001628280-26-066331:3
- 822 shares@ US$6.52230.0001% mcap0.1% of flowCommon StockSEC:0001628280-26-066331:0
- 4,728 shares@ US$26.930.0038% mcap21.4% of flowCommonSEC144:0001628280-26-065989
- 3,674 shares@ US$25.00090.0025% mcap4.2% of flowCommon StockSEC:0001628280-26-062732:0
- 1,019 shares@ US$7.510.0002% mcap0.2% of flowCommon StockSEC:0001628280-26-062490:1
- 2,255 shares@ US$8.630.0005% mcap0.4% of flowCommon StockSEC:0001628280-26-062490:2
- 822 shares@ US$6.52230.0001% mcap0.1% of flowCommon StockSEC:0001628280-26-062490:0
- 4,730 shares@ US$24.180.0031% mcap2.4% of flowCommon StockSEC:0001628280-26-062490:3
- 341,980 shares@ US$25.000.23% mcap100.0% of flowCommonSEC144:0001628280-26-062242
- 4,730 shares@ US$24.180.0028% mcap18.7% of flowCommonSEC144:0001628280-26-062042
- 9,989 shares@ US$25.02610.0060% mcap7.2% of flowCommon StockSEC:0001628280-26-061444:0
- 13,663 shares@ US$25.02620.0082% mcap100.0% of flowCommonSEC144:0001628280-26-060930
25 of 703 declarations
About Arcutis Biotherapeutics, Inc.
On February 4, 2020, Frazier Life Sciences VIII, L.P. (10% Owner) and Patrick J. Heron (Director) each bought EUR 7,683,320 at Arcutis Biotherapeutics, Inc.; with three other filers, the purchases between February 3, 2020 and February 4, 2020 reach EUR 37,021,076. Jonathan Silverstein (Director) bought EUR 6,300,582 on October 2, 2020. In all, 29 purchases worth EUR 63,773,199 (median EUR 77,525). For those 29 purchases, stored past results show a median 90-day return of 8.4%, positive in 83% of cases (stored results, not a forecast).
The 344 sales amount to EUR 55,122,843 (median EUR 43,012), so purchases are 8% of market trades. The largest are Orbimed Advisors LLC's: EUR 6,199,015 on June 24, 2022, EUR 3,369,464 on April 7, 2022 and EUR 3,250,262 on April 6, 2022.
Read moreShow less
This US healthcare and pharma company, valued at USD 4.0 billion, has 693 filings covering trades from February 3, 2020 to October 20, 2026, including 147 option exercises. Howard G. Welgus (Director) signed 175. The last twelve months hold 138, with 75 sales and no purchase.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
